Several other analysts have also recently commented on the stock. Analysts at Jefferies Group raised their price target on shares of Boston Scientific from $7.60 to $8.30 in a research note to investors on Wednesday. They now have a hold rating on the stock. Separately, analysts at RBC Capital reiterated an outperform rating on shares of Boston Scientific in a research note to investors on Wednesday. They now have a $8.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a hold rating on shares of Boston Scientific in a research note to investors on Wednesday. They now have a $7.20 price target on the stock, up previously from $6.70.
Eight equities research analysts have rated the stock with a buy rating, eighteen have given a hold rating, and one has assigned a sell rating to the stock. The stock has a consensus rating of – and a consensus price target of $7.65.
Boston Scientific traded up 0.13% on Wednesday, hitting $7.54. Boston Scientific has a 52-week low of $4.79 and a 52-week high of $7.73. The stock’s 50-day moving average is currently $6.. The company’s market cap is $10.222 billion.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.